CD1d–invariant natural killer T-cell receptor complex (CD1d–iNKT TCR complex)

The CD1d–invariant natural killer T-cell receptor (iNKT TCR) complex is a unique immunological synapse formed between the non-polymorphic MHC class I-like molecule CD1d and the semi-invariant T-cell receptor of invariant Natural Killer T (iNKT) cells [1, 7]. In humans, this TCR typically comprises a Vα24-Jα18 alpha chain paired with a Vβ11 beta chain, which specifically recognizes lipid and glycolipid antigens presented in the hydrophobic groove of CD1d [7, 10]. Upon recognition of an agonist ligand, such as the marine sponge-derived alpha-galactosylceramide (α-GalCer), the complex initiates a rapid and potent signaling cascade that results in the immediate secretion of both pro-inflammatory (Th1) and immunomodulatory (Th2) cytokines [1, 4]. This dual capacity allows iNKT cells to bridge innate and adaptive immunity by activating dendritic cells, natural killer cells, and B cells [1, 2]. The complex is a major target for cancer immunotherapy, where it is leveraged to stimulate antitumor responses, as well as in the treatment of autoimmune diseases and infections [3, 8]. However, therapeutic application is challenged by the risk of cytokine storm and the induction of long-term iNKT cell anergy following repeated or potent stimulation [3, 11].

Other names

CD1d–iNKT TCR complexCD1d-restricted invariant natural killer T-cell receptor complexVα24-Jα18/Vβ11 TCR–CD1d complexType I NKT TCR–CD1d complexiNKT TCR–CD1d complexCD1d–invariant NKT TCR complex

Agonist ligands bind to the hydrophobic groove of CD1d, which is then recognized by the invariant TCR of iNKT cells to form a ternary complex; this interaction triggers rapid intracellular signaling leading to a massive burst of Th1 and Th2 cytokines and subsequent activation of the broader immune system.